Barclays’s Juno Therapeutics, Inc. JUNO Stock Holding History

Barclays’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-900	Closed	-$41K	–	7595
2017 Q4	$41K	Sell	900 -208,800	-100%	-$10.4M	﹤0.01%	5878
2017 Q3	$9.41M	Sell	209,700 -36,100	-15%	-$1.23M	0.01%	1089
2017 Q2	$7.35M	Buy	+245,800	New	+$6.07M	0.01%	1184
2016 Q3	–	Sell	-40,000	Closed	-$1.54M	–	6946
2016 Q2	$1.54M	Buy	+40,000	New	+$1.66M	﹤0.01%	2222

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Barclays's JUNO Position: Q1 2018 in Review

Barclays sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 124,704 shares — an estimated $5.7M sold.

Barclays first reported a position in JUNO in Q1 2015 and held it in 12 quarters. The position peaked at $10.6M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Barclays reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Barclays sold 124,704 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $5.7M.
Barclays first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
Barclays's Juno Therapeutics, Inc. position peaked at $10.6M in Q3 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Barclays's 13F filing for Q1 2018, filed 15 May 2018.